Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. news (Ticker: SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics Ltd. stock.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company that regularly publishes updates on its dual business model: development of inflammation and immunology (I&I) biologics and operation of a boutique biologics CDMO under the Scinai Bioservices brand. The news flow around SCNI reflects both scientific progress and the evolution of its contract development and manufacturing activities.
Company press releases highlight several recurring themes. On the R&D side, Scinai reports advances in its NanoAb-based I&I pipeline, including anti‑IL‑17 programs for psoriasis and additional NanoAbs arising from collaborations with the Max Planck Society and University Medical Center Göttingen. News items also cover the PC111 program, a first‑in‑class human anti-Fas Ligand monoclonal antibody being developed for severe dermatological conditions such as pemphigus vulgaris and SJS/TEN through an option agreement to acquire Pincell Srl.
On the CDMO side, Scinai’s news frequently addresses growth in Scinai Bioservices, including revenue contributions from its U.S. subsidiary, new service orders, and infrastructure expansions such as an Israel Innovation Authority grant to fund an advanced sterile fill‑and‑finish system. These updates provide context on how the company is expanding its role as a boutique CDMO serving early-stage biotech clients in Israel, the United States, and Europe.
Investors and industry observers can also find announcements on equity financing arrangements, grant applications and outcomes, participation in sector conferences, and governance or cost-structure changes reported via Form 6‑K. This news page aggregates those releases so readers can follow SCNI’s financial results, pipeline milestones, CDMO capacity developments, and strategic transactions over time.
Scinai (NASDAQ: SCNI) completed the acquisition of 100% of Recipharm Israel Ltd., adding a cGMP Yavne manufacturing site and expanding Scinai's CDMO footprint and technical scope.
The companies also signed a long-term commercial collaboration granting Scinai preferred early-stage status and access to Recipharm's global manufacturing network under predefined terms, plus a Master Quality Agreement and Tech Transfer Framework to streamline program transitions.
Scinai (Nasdaq: SCNI) announced that CEO Amir Reichman will co-lead a Manufacturers Association roundtable titled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale" on January 19, 2026 at Expo Tel Aviv during HealthIL Week 2026.
The session will focus on early-stage development, CMC and analytical capabilities, clinical GMP manufacturing, access to laboratory infrastructure, and readiness for later-stage and commercial manufacturing in Israel.
Participants will include government agencies, local and international biopharma companies, CDMOs, multinationals, and investors; the discussion aims to identify structural gaps and collaboration models to strengthen Israel's biopharma manufacturing ecosystem over the next 5–10 years.
Scinai (NASDAQ: SCNI) reported nine-month 2025 results and corporate updates. Revenues were $1,049k vs $452k a year earlier, driven by CDMO expansion including $502k from its U.S. subsidiary. R&D expenses fell to $1,799k from $4,195k; MG&A were $1,929k. Financial expenses, net were $607k versus financial income of $13,374k in 2024. Net loss was $6,244k versus net profit $7,026k year-ago. Cash and short-term deposits totaled $3,005k.
Operational highlights: a NIS 809k (~$246k) non-dilutive IIA grant for sterile fill-finish (installation Q1 2026, commercial Q2 2026); two separate €15m STEP grant decisions expected Q1 2026 for NanoAb programs; PC111 €12m FENG grant was not approved and Scinai is re-evaluating options, with a Pincell SPA option conditional on demonstrating $3m earmarked by Feb 28, 2026.
Scinai (NASDAQ: SCNI) received a non-dilutive Israel Innovation Authority grant of NIS 809,000 (~$246,000), funding ~66% of a NIS 1.23 million (~$373,000) project to acquire and install an advanced small-batch sterile fill-and-finish system.
Installation and qualification are expected in Q1 2026 with commercial operation planned in Q2 2026. The upgrade aims to expand Scinai Bioservices' GMP fill-and-finish capacity, enable rapid batch turnaround across primary packaging formats, and support clients in Israel, the U.S., and Europe while meeting EMA and FDA cGMP standards.
Scinai also continues R&D programs and holds an option to acquire PinCell Srl (PC111) and retains licensing options for NanoAbs from MPG and UMG.
Scinai Immunotherapeutics (NASDAQ: SCNI) reported its H1 2025 financial results, showcasing growth in its CDMO business. Revenues reached $773,000, up from $284,000 in H1 2024, while net loss decreased to $4.13 million from $4.48 million.
The company strengthened its balance sheet through a $4.2 million raise via its Standby Equity Purchase Agreement. CDMO operations generated $1.0 million in total orders for 2025, with $850,000 already invoiced. R&D initiatives include advancing anti-IL-17 NanoAb programs, pursuing EU grant funding, and exploring an acquisition opportunity with PinCell srl.
Scinai Immunotherapeutics (NASDAQ:SCNI) announced a new peer-reviewed publication validating PC111, their first-in-class human anti-Fas Ligand monoclonal antibody, as a potential disease-modifying therapy for pemphigus and SJS/TEN. The research, published in the Journal of Dermatological Treatment, demonstrates PC111's ability to prevent blister formation across multiple study models.
The study confirms PC111's unique non-immunosuppressive mechanism, acting locally at the keratinocyte level. The treatment represents a market opportunity exceeding $1 billion annually. Scinai and Pincell plan to advance PC111 through IND-enabling studies, with potential market entry in 3-4 years. The program may receive up to 80% cost coverage through a €15 million FENG grant, pending Q3 2025 decision.
Scinai Immunotherapeutics (NASDAQ:SCNI) announces that Dr. Roberta Lotti from Pincell Srl has received the prestigious "Oscar of Italian Dermatology" for her groundbreaking research on PC111, a first-in-class anti-Fas Ligand monoclonal antibody. The award recognizes Dr. Lotti's paper demonstrating PC111's efficacy in treating pemphigus through a novel, non-immunosuppressive approach.
PC111, which Scinai has rights to through a strategic option agreement to acquire Pincell srl, targets soluble Fas Ligand (sFasL) in Pemphigus Vulgaris (PV) and Stevens-Johnson/Toxic Epidermal Necrolysis (SJS/TEN). The research confirms that PC111 blocks blister formation by inhibiting keratinocyte apoptosis, representing a potential paradigm shift from current immunosuppressive treatments.